To study the prevalence and clinical significance of DNAJB8 overexpression in COAD L-OHP resistance, we quantified the expression of DNAJB8 by immunohistochemistry (IHC) in a cohort of 220 COAD patients who were treated with postoperative L-OHP chemotherapy. Here, DNAJB8 is linked to colon adenocarcinoma.